Neurocrine Biosciences (NBIX) Common Equity (2010 - 2026)

Neurocrine Biosciences' Common Equity history runs 17 years deep, the most recent figure standing at $3.4 billion for Q1 2026.

• Quarterly Common Equity rose 34.38% year-over-year to $3.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 billion (up 34.38% YoY) and the FY2025 annual result came in at $3.3 billion, up 25.62% from the prior year.
• Common Equity was $3.4 billion for Q1 2026 at Neurocrine Biosciences, up from $3.3 billion in the prior quarter.
• Across five years, Common Equity topped out at $3.4 billion in Q1 2026 and bottomed at $1.4 billion in Q1 2022.
• A 5-year average of $2.3 billion and a median of $2.4 billion in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity surged 41.65% — and 2025, when it gained 6.27%.
• Neurocrine Biosciences' Common Equity stood at $1.7 billion in 2022, then soared by 30.69% to $2.2 billion in 2023, then gained by 16.03% to $2.6 billion in 2024, then rose by 25.62% to $3.3 billion in 2025, then gained by 4.74% to $3.4 billion in 2026.
• Business Quant data shows NBIX's Common Equity at $3.4 billion in Q1 2026, $3.3 billion in Q4 2025, and $3.0 billion in Q3 2025.